Rid­ing on pos­i­tive PhI­II NASH da­ta, Madri­gal rais­es $300M for road to FDA

Madri­gal Phar­ma­ceu­ti­cals isn’t wast­ing any time cap­i­tal­iz­ing on its big NASH win, haul­ing in more than $300 mil­lion to push the pro­gram for­ward.

The biotech’s shares had dou­bled af­ter it re­port­ed that its NASH drug, resme­tirom, met its ear­ly end­points in a Phase III tri­al, mark­ing a rare suc­cess in a field lit­tered with fail­ures. Ex­ecs said they plan to file for ac­cel­er­at­ed ap­proval ear­ly next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER